Edison Investment Research - Xintela AB (A2AF7J) Xintela - Termination of coverage

Report

Edison Investment Research

Sean Conroy

Xintela - Termination of coverage

Edison Investment Research is terminating coverage on Xintela (XINT), TXT e-solutions (TXT), HUTCHMED (HCM) and Schaltbau Holding (SLT). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

10/01/2022 1 EN

Underlying

Xintela AB

Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.

See profile

SE0007756903 Nasdaq Nordic Stockholm Sweden

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Xintela - Termination of coverage

January 10, 2022 January 10, 2022 1 EN

Edison Investment Research

Xintela - Approaching major milestones

Xintela’s Q321 report provides key updates on the company’s pipeline and business plans. Lead programme XSTEM-OA will begin patient enrolment in early 2022, with the aim of showing disease-modifying osteoarthritis drug (DMOAD) properties. A second clinical study, assessing XSTEM in difficult-to-heal venous leg ulcers, is planned for mid-2022 and offers a potentially faster path to market. Subsidiary Targinta has advanced towards preclinical development following selection of a drug candidate (TARG10) for triple negative breast cancer (TNBC) with spin-off formalities picking up speed. We expect...

December 10, 2021 December 10, 2021 1 EN

Accsys Technologies - Upgrading guidance for the full year

Accsys Technologies had a strong H125 with a return to revenue growth and gross margin exceeding its target of 30%. Adjusted EBITDA improved on the back of better than expected volume growth from the plant in Arnhem. The company has simplified and de-risked the group through the successful start-up of the plant in the United States and the decision to discontinue the project in Hull. After the good start of the year, Accsys increased guidance for the full year, with underlying profitability expected to improve in H2 as Accoya USA continues to ramp up.

November 26, 2024 November 26, 2024 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Market outperformance again in FY24

Topps Tiles (TPT) has reported a good profit outturn for FY24, ahead of our prior expectations, which is encouraging in the context of the challenging external environment. Management believes the overall revenue decline of 5% means TPT has once again outperformed the market that it estimates to have declined by 10–15%. TPT has made good early progress on the key growth areas under its recently announced Mission 365 strategy, which are expected to drive the bulk of the growth in the medium term. With respect to the outlook for FY25, TPT has returned to positive revenue growth in the first eigh...

November 26, 2024 November 26, 2024 1 EN

Toby Thorrington

Toby Thorrington

Nabaltec - Resilience and margin expansion

Nabaltec recorded revenue growth across the group of 1.5% y-o-y to €158.2m at 9M24, with sales volumes increasing 7.9% y-o-y despite selling prices falling. Functional Fillers revenue grew by 3.8% y-o-y to €114.1m due to strong demand for its viscosity optimised and fine precipitated aluminium hydroxides. Speciality Alumina revenue, however, decreased 4.1% y-o-y, partially offsetting group revenue growth due to a lack of impetus for reactive alumina in the wider market. Group EBIT grew 28.2% y-o-y to €16.8m (10.3% margin), due to higher capacity utilisation and lower costs of materials, energy...

November 25, 2024 November 25, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Xintela - Termination of coverage

Xintela - Termination of coverage

Xintela - Approaching major milestones

Accsys Technologies - Upgrading guidance for the full year

Topps Tiles - Market outperformance again in FY24

Nabaltec - Resilience and margin expansion

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe